decisionhealth Newsletters, Coder Pink Sheets - 2003 Issue 3 (March)
Strattera
Subscribe or sign in to view the full article.
Article Overview
This article covers an early discussion of Strattera (atomoxetine) after its approval, with emphasis on refill visit frequency, monitoring expectations, and how clinicians were thinking about follow-up compared with stimulant medications used for ADHD. It is intended for readers who need a general overview of prescribing follow-up considerations, medication monitoring, and pediatric ADHD care context.
Why This Topic Matters
It helps readers understand the clinical and operational context surrounding early use of a newly approved ADHD medication, especially when planning follow-up frequency and monitoring workflows.
Article Sections
-
Strattera: Fewer refill visits? Too soon to say
Discusses early follow-up considerations for a newly approved ADHD medication and compares general monitoring expectations with those used for stimulant therapy. It also notes concerns related to controlled-substance status and diversion risk.
What You Will Learn
- How the article frames early monitoring considerations for a newly approved ADHD medication
- How follow-up frequency was being discussed in relation to ADHD stimulant therapy
- What general concerns were raised about medication control status and diversion
- Which specialty and organizational context informed the discussion
Who Should Read This
- Pediatricians
- Primary care clinicians
- ADHD care teams
- Medical coders and healthcare documentation reviewers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com